Celldex Therapeutics (CLDX) Operating Margin (2010 - 2026)
Celldex Therapeutics (CLDX) recorded quarterly Operating Margin of 562900.0% in Q1 2026, down 681.51% quarter-over-quarter from 72027.27% in Q4 2025, and down 55387281.0% on a YoY basis from N/an in Q1 2025.
Celldex Therapeutics (CLDX) Operating Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Operating Margin history runs 17 years deep, the most recent figure standing at 562900.0% for Q1 2026.
- In Q1 2026, Operating Margin fell 55387281.0% year-over-year to 562900.0%; the TTM figure through Mar 2026 stood at 35688.45% (down 3281494.0% YoY), while the FY2025 annual figure was 18599.81%, down 1582092.0% from the prior year.
- Operating Margin was 562900.0% for Q1 2026 at Celldex Therapeutics, down from 72027.27% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 1152.92% in Q4 2023 to a low of 562900.0% in Q1 2026.
- Historically, Operating Margin has averaged 46927.28% across 5 years, with a median of 7776.22% in 2022.
- The sharpest annual moves came in 2025 and 2026: Operating Margin surged 1700357 bps in 2025, then sank 55387281 bps in 2026.
- A 5-year view of Operating Margin shows it stood at 1728.77% in 2022, then jumped by 33 bps to 1152.92% in 2023, then tumbled by 314 bps to 4768.26% in 2024, then tumbled by 1411 bps to 72027.27% in 2025, then slumped by 682 bps to 562900.0% in 2026.
- The last three Operating Margin figures came in at 562900.0% (Q1 2026), 72027.27% (Q4 2025), and 8747.53% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn | -562,900.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -562,900.00% |
| Dec 31, 2025 | -72,027.27% |
| Jun 30, 2025 | -8,747.53% |
| Mar 31, 2025 | -9,027.19% |
| Dec 31, 2024 | -4,768.26% |
| Sep 30, 2024 | -1,633.53% |
| Jun 30, 2024 | -1,854.16% |
| Mar 31, 2024 | -26,030.77% |
| Dec 31, 2023 | -1,152.92% |
| Sep 30, 2023 | -2,718.46% |
| Jun 30, 2023 | -12,389.93% |
| Mar 31, 2023 | -3,357.91% |
| Dec 31, 2022 | -1,728.77% |
| Sep 30, 2022 | -6,804.91% |
| Jun 30, 2022 | -22,328.83% |
| Mar 31, 2022 | -13,366.09% |
| Dec 31, 2021 | 10,792.81% |
| Sep 30, 2021 | -13,610.46% |
| Jun 30, 2021 | -386.21% |
| Mar 31, 2021 | -2,429.05% |